Capivasertib (Truqap,Capivadx)

Capivasertib is the first approved highly selective ATP-competitive AKT kinase inhibitor, and is commonly used in combination with fulvestrant.

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Capivasertib Drug News

First-in-Class Combination Therapy for Advanced HR-Positive Breast Cancer! Truqap + Fulvestrant Appr

According to the American Cancer Society, breast cancer is the most common cancer among women in the United States. HR-positive breast cancer (express···【More】
Update: 02 Apr,2026Source: BigbearViews: 82
Promising Efficacy Demonstrated for Truqap Combination Therapy in Phase 3 Trial for the Treatment of

AstraZeneca recently announced positive results from the Phase 3 CAPItello-281 clinical trial. The analysis showed that in patients with PTEN-deficien···【More】
Update: 02 Apr,2026Source: BigbearViews: 80
Capivasertib in Combination with Faslodex Demonstrates Significant Efficacy in Phase 3 Trial for HR-

AstraZeneca recently announced positive top-line results from the Phase 3 CAPItello-291 trial. This global, double-blind, randomized Phase 3 study for···【More】
Update: 02 Apr,2026Source: BigbearViews: 82